Navigation Links
FDA Approves NovoLog(R) Labeling Update
Date:7/15/2009

ons by syringe.

Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your NovoLog(R) dose may change if you take other medicines.

NovoLog(R) has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

The most common side effect of NovoLog(R) is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit www.novonordisk-us.com.

(1) Revised NovoLog Prescribing Information. "Dos
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Fitness Management Group, Inc. Approves Sale of the Company
2. Cardinal Health Board of Directors Approves CareFusion Spinoff
3. Video: FDA Approves Hologics Adiana(R) Permanent Contraception System
4. European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
5. FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
6. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
7. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
8. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
9. ClearWay Minnesota(SM) Board Approves Four Regional Grants
10. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
11. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Children had half as many emergency department visits if ... five or more days a week, according to new ... Hospital and Johns Hopkins University. , The new study ... of Pediatrics and will be presented at the ... important step in understanding where primary care practices and ...
(Date:6/19/2013)... are increasingly common on college campuses, but are ... up"? A new study by researchers with The ... published online by the Archives of Sexual ... behaviors associated with sexual hookups, particularly among first-year ... negative emotional and physical health outcomes as a ...
(Date:6/19/2013)... block the body,s system for repairing damage to the ... unlikely as it may seem, those compounds are sparking ... driven by a mutation in BRCA, a gene that ... the mutation. The compounds, termed PARP inhibitors, are the ... of Chemical & Engineering News . C&EN is ...
(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...
(Date:6/19/2013)... Alternatives, a revolutionary new treatment facility located ... drugs while allowing them to continue drinking alcohol. Drs. ... believe that abstinence-only approaches force people to wait until ... this approach hurts instead of helping. It is ... need treatment for addiction but only 3 million seek ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3
... way to treat castrate resistant cells in prostate cancer ... For more than 60 years the main way ... the hormones that fuel growth of the cancer cells. ... the tumour growth resumes, the disease in incurable. The ...
... , ... ... ... ...
... ... ... ... ...
... ... ... of complex government regulation some of the stand-out questions include:, , ,   ... How are these standards impacted by the convergence of media and conflation of traditional media ...
... ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Effective prostate cancer treatment discovery 2Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 2Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 3Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 4Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 2Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 3Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 4Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 5Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 6Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 7Health News:Alan Chapell, President of Chapell & Associates to Deliver Keynote at the Next AdMonsters US Leadership Forum 2Health News:Alan Chapell, President of Chapell & Associates to Deliver Keynote at the Next AdMonsters US Leadership Forum 3Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 2Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 3Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 4Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 5Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 6Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 7Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 8Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 2Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 3Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 4Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 5Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 6
(Date:6/19/2013)... /PRNewswire-iReach/ -- Today leading web researchers Change Sciences Group ... web sites for usability, engagement, and conversion. The rankings ... which compares how people experience sites with competitors and ... The top three performers are easier to use, more ... performers have usability problems, lack aspects of design that ...
(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...
(Date:6/18/2013)... Quebec , June 18, 2013 Valeant ... TSX: VRX) (the "Company") announced today that VPII Escrow ... the Company, has launched its offer of approximately $3.2 ... "Notes").  The Notes will be due in 2021 and ... The Company intends to use the net proceeds ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... 2011 When consumers are offered a cost-neutral choice ... store or through a mail-order pharmacy, they split their ... study from CVS Caremark (NYSE: CVS ) ... study, published in the January edition of the ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced ... BMN 701, a novel fusion protein of insulin-like growth factor ... treatment of Pompe disease. "We have a strong ... medical needs and expect to leverage our clinical and regulatory ...
Cached Medicine Technology:CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions 2CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions 3BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease 2BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease 3
... Blood Collection Tubes are used ... blood samples for use with ... chemistry cartridges requiring either 95 ... sample. These tubes are Mylar-wrapped ...
... FEMTO LDV, the first compact, mobile femtosecond ... a versatile, powerful platform for a wide ... basic system addresses the demand of refractive ... is consistent with an efficient LASIK work-flow. ...
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
Medicine Products: